

CATALYST PHARMACEUTICAL PARTNERS, INC.  
Form SC 13G  
November 05, 2012  
CUSIP No. 14888U101

13G

Page - 1 - of 6 Pages

## **SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

### **SCHEDULE 13G**

**(Rule 13d-102)**

**INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT**

**TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED**

**PURSUANT TO § 240.13d-2**

**(Amendment No. )\***

# **CATALYST PHARMACEUTICAL PARTNERS, INC.**

**(Name of Issuer)**

**Common Stock, \$0.001 par value per share**  
**(Title of Class of Securities)**

**14888U101**  
(CUSIP Number)

**October 26, 2012**  
(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

\* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities Exchange Act of 1934 ( Act ) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

**1 NAME OF REPORTING PERSON**

BioMarin Pharmaceutical Inc.

**2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP**

(a)  (b)

**3 SEC USE ONLY**

**4 CITIZENSHIP OR PLACE OF ORGANIZATION**

Delaware

**5 SOLE VOTING POWER**

**NUMBER OF  
SHARES 3,448,276**

**6 SHARED VOTING POWER**

**BENEFICIALLY**

**OWNED BY**

**0**

**EACH 7 SOLE DISPOSITIVE POWER**

**REPORTING**

**PERSON 3,448,276**

**8 SHARED DISPOSITIVE POWER**

**WITH**

**0**

**9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON**

**3,448,276**

**10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES**

**11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)**

**12** **9.9%**  
**TYPE OF REPORTING PERSON**

CO

- Item 1.**
- (a) **Name of Issuer:**  
Catalyst Pharmaceutical Partners, Inc., a Delaware corporation (the Issuer )
- (b) **Address of Issuer's Principal Executive Offices:**  
355 Alhambra Circle 1500  
Coral Gables, Florida 33134
- Item 2.**
- (a) **Name of Person Filing:**  
BioMarin Pharmaceutical Inc., a Delaware corporation
- (b) **Address of Principal Business Office:**  
105 Digital Drive  
Novato, California 94949
- (c) **Citizenship:**  
Delaware
- (d) **Title of Class of Securities:**  
Common Stock, par value \$0.001 per share ( Common Stock )
- (e) **CUSIP Number:**  
14888U101
- Item 3.** **If this statement is filed pursuant to §240.13d-1(b), or §240.13d-2(b) or (c), check whether the person filing is a:**
- (a) .. Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
- (b) .. Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
- (c) .. Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
- (d) .. Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
- (e) .. An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
- (f) .. An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
- (g) .. A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

- (h) " A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
- (i) " A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3);
- (j) " A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J);
- (k) " Group, in accordance with § 240.13d-1(b)(1)(ii)(K).

If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

#### Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount Beneficially Owned:

**3,448,276\***

- (b) Percent of Class:

**9.9%**

- (c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote: **3,448,276**

(ii) Shared power to vote or to direct the vote: **0**

(iii) Sole power to dispose or to direct the disposition of: **3,448,276**

\* The shares of the Issuer's Common Stock that are the subject of this Schedule 13G are issuable by the Issuer pursuant to the terms of a Convertible Promissory Note and Note Purchase Agreement, effective as of October 26, 2012 in the aggregate principal amount of \$5,000,000 (the "Convertible Note"). The Convertible Note will be automatically converted into shares of Common Stock on (the "Conversion Date") the earlier of (i) 30 days after announcement by the Issuer of top-line data from the Issuer's Phase II(b) clinical trial evaluating the use of CPP-109 (the Issuer's formulation of vigabatrin, a GABA aminotransferase inhibitor) for the treatment of cocaine addiction or (ii) March 31, 2013 and may therefore become issuable within 60 days after October 26, 2012. The number of shares issuable upon conversion of the Convertible Note is calculated by dividing the aggregate principal amount of the note, \$5,000,000 by the "Conversion Price" in effect on the Conversion Date. The Conversion Price is the dollar weighted average price of the Common Stock for the 15 business day period prior to the Conversion Date, multiplied by 0.9; provided, however, that the Conversion price shall not be less than \$0.75 per share or more than \$2.50 per share. Accordingly, the number of shares beneficially owned by BioMarin Pharmaceutical Inc. will fluctuate from time to time based on the underlying trading price and volume of the Issuer's Common Stock. The number of shares of Common Stock reflected in this Schedule 13G were calculated as of the close of trading on November 1, 2012.

(iv) Shared power to dispose or to direct the disposition of: **0**

**Item 5. Ownership of Five Percent or Less of a Class.**

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following ".

**Item 6. Ownership of More than Five Percent on Behalf of Another Person.**

Not Applicable

**Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.**

Not Applicable

**Item 8. Identification and Classification of Members of the Group.**

Not Applicable

**Item 9. Notice of Dissolution of Group.**

Not Applicable

**Item 10. Certification.**

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

**SIGNATURE**

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: **November 2, 2012**

**BioMarin Pharmaceutical Inc.**

By: /s/ G. Eric Davis

Name: G. Eric Davis

Title: Senior Vice President, General Counsel and Secretary